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Antimicrobial-impregnated central venous catheters for 
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an open-label, parallel-group, pragmatic, randomised 
controlled trial
Ruth Gilbert, Michaela Brown, Naomi Rainford, Chloe Donohue, Caroline Fraser, Ajay Sinha, Jon Dorling, Jim Gray, William McGuire, 
Carrol Gamble, Sam J Oddie, on behalf of the PREVAIL trial team*
Summary
Background Bloodstream infection is associated with high mortality and serious morbidity in preterm babies. 
Evidence from clinical trials shows that antimicrobial-impregnated central venous catheters (CVCs) reduce catheter-
related bloodstream infection in adults and children receiving intensive care, but there is a paucity of similar evidence 
for babies receiving neonatal intensive care.
Methods This open-label, parallel-group, pragmatic, randomised controlled trial was done in 18 neonatal intensive 
care units in England. Newborn babies who needed a peripherally inserted CVC (PICC) were allocated randomly (1:1) 
to receive either a PICC impregnated with miconazole and rifampicin or a standard (non-antimicrobial-impregnated) 
PICC. Random allocation was done with a web-based program, which was centrally controlled to ensure allocation 
concealment. Randomisation sequences were computer-generated in random blocks of two and four, and stratified by 
site. Masking of clinicians to PICC allocation was impractical because rifampicin caused brown staining of the 
antimicrobial-impregnated PICC. However, participant inclusion in analyses and occurrence of outcome events were 
determined following an analysis plan that was specified before individuals saw the unblinded data. The primary 
outcome was the time from random allocation to first microbiologically confirmed bloodstream or cerebrospinal fluid 
(CSF) infection between 24 h after randomisation and 48 h after PICC removal or death. We analysed outcome data 
according to the intention-to-treat principle. We excluded babies for whom a PICC was not inserted from safety 
analyses, as these analyses were done with groups defined by the PICC used. This trial is registered with ISRCTN, 
number 81931394.
Findings Between Aug 12, 2015, and Jan 11, 2017, we randomly assigned 861 babies (754 [88%] born before 32 weeks 
of gestation) to receive an antimicrobial-impregnated PICC (430 babies) or standard PICC (431 babies). The median 
time to PICC removal was 8·20 days (IQR 4·77–12·13) in the antimicrobial-impregnated PICC group versus 
7·86 days (5·00–12·53) days in the standard PICC group (hazard ratio [HR] 1·03, 95% CI 0·89–1·18, p=0·73), with 
46 (11%) of 430 babies versus 44 (10%) of 431 babies having a microbiologically confirmed bloodstream or CSF 
infection. The time from random allocation to first bloodstream or CSF infection was similar between the two 
groups (HR 1·11, 95% CI 0·73–1·67, p=0·63). Secondary outcomes relating to infection, rifampicin resistance in 
positive blood or CSF cultures, mortality, clinical outcomes at neonatal unit discharge, and time to PICC removal 
were similar between the two groups, although rifampicin resistance in positive cultures of PICC tips was higher in 
the antimicrobial-impregnated PICC group (relative risk 3·51, 95% CI 1·16–10·57, p=0·018). 60 adverse events were 
reported from 49 (13%) patients in the antimicrobial-impregnated PICC group and 50 events from 45 (10%) babies 
in the standard PICC group.
Interpretation We found no evidence of benefit or harm associated with miconazole and rifampicin-impregnated 
PICCs compared with standard PICCs for newborn babies. Future research should focus on other types of 
antimicrobial impregnation of PICCs and alternative approaches for preventing infection.
Funding UK National Institute for Health Research Health Technology Assessment programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access license under the CC BY 4.0 license.
Introduction
Bloodstream infection is the most common serious 
complication associated with the use of central venous 
catheters (CVCs) in newborn babies. Microbial pathogens 
adhere to the catheter material and secrete a biofilm1 that 
protects them from circulating antimicrobial drugs, 
enabling sustained colonisation.2 CVC removal is often 
needed to clear the infection.
Catheter-related bloodstream infection has been 
reported to occur in up to 30% of neonates, with the 
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highest rates in babies who are born very prematurely 
(before 32 weeks of gestation).3,4 The organisms most 
frequently isolated from preterm babies are coagulase-
negative staphylococci, Gram-negative bacilli, other Gram-
positive cocci (Staphylococcus aureus and enterococci), and 
fungi (predominantly Candida species).5 Bloodstream 
infection increases the risk of death and serious morbidity 
in very preterm babies,6,7 and is associated with long-term 
adverse neuro developmental outcomes.8,9
Use of antimicrobial-impregnated CVCs is recom-
mended in US and UK national guidelines for patients at 
high risk of infection.10,11 A randomised trial involving 
1485 children (aged 1 week to 18 years) receiving 
paediatric intensive care in the UK showed that use of 
antimicrobial-impregnated CVCs versus standard (non-
impregnated) CVCs reduced bloodstream infection.12 
However, there are no recommendations for newborn 
babies because few antimicrobial-impregnated catheters 
are narrow enough for preterm babies and there is a 
paucity of evidence from adequately powered randomised 
trials.13,14 The PREVAIL trial aimed to address this 
evidence gap by determining the effectiveness of an 
antimicrobial-impregnated CVC licensed for newborn 
infants. We compared use of a miconazole and 
rifampicin-impregnated CVC with a standard (non-
impregnated) CVC for reduction of bloodstream 
infection, morbidity, and mortality in newborn babies 
receiving intensive care.
Methods
Study design and participants
This open-label, parallel-group, pragmatic, randomised 
controlled trial was done in 18 neonatal units in England. 
Full details of the amended trial protocol (version 5.0; 
published April 26, 2017), research ethics approval (from 
Yorkshire and the Humber—Sheffield—Health Research 
Authority reference no 14-YH-1202), and statistical 
analysis plan are available online.
All babies requiring a narrow-gauge (French gauge 1) 
peripherally inserted CVC (PICC) were eligible to partici-
pate. The reason for insertion was not requested by the trial 
team, but PICCs are usually used for parenteral nutrition 
and drug administration—70% of babies in neonatal units 
born before 32 weeks of gestation have a PICC inserted 
(Fraser C, National Neonatal Research Database, England, 
personal communication). Babies who had previously 
entered this trial and those who had a known allergy or 
hypersensitivity to rifampicin or miconazole were excluded. 
For more on the PREVAIL trial 
see http://prevailtrial.org.uk/
Research in context
Evidence before this study
We searched Cochrane Central Register of Controlled Trials, 
Embase, and MEDLINE on March 29, 2018, and ClinicalTrials.
gov and WHO International Clinical Trials Registry Platform on 
April 3, 2018, for studies evaluating the effectiveness of 
antimicrobial-impregnated central venous catheters (CVCs) 
compared with any other type of CVC for reducing bloodstream 
infection in newborn infants, children, and adults. We included 
systematic reviews or meta-analyses of randomised controlled 
trials of miconazole and rifampicin-impregnated or minocycline 
and rifampicin-impregnated CVCs published since 2008 and 
randomised controlled trials in children or newborn infants 
published since the searches conducted by the systematic 
reviews that were included in our evidence review. We used 
search terms related to CVCs, antimicrobial impregnation, and 
infection (see appendix for full search terms). We identified 
11 randomised controlled trials of central venous catheters 
(CVCs) impregnated with rifampicin combined with another 
antimicrobial agent (appendix). Two trials compared 
miconazole and rifampicin-impregnated CVCs and standard 
CVCs. One of these trials involved newborn infants and was 
published only as an abstract. Neither trial reported a significant 
difference in bloodstream infection. Nine randomised 
controlled trials of minocycline and rifampicin-impregnated 
CVCs compared with standard CVCs found consistent evidence 
of reduced catheter-related bloodstream infection in children 
and adults. One trial reported reduced bloodstream infection 
from any cause in children (appendix). A 2015 Cochrane review 
of antimicrobial-impregnated CVCs in newborn babies 
concluded that, given the paucity of evidence, a large, simple, 
and pragmatic randomised controlled trial of this intervention 
was needed to guide policy and practice.
Added value of this study
The PREVAIL trial showed that use of miconazole and 
rifampicin-impregnated, percutaneously inserted CVCs 
compared with use of standard CVCs did not reduce the risk of 
any bloodstream infection or catheter-related bloodstream 
infection, other morbidity, or mortality in newborn infants. To 
our knowledge, this is the largest trial to date of this 
intervention and the validity is enhanced by the 
methodological quality and power. The findings of this study 
are broadly applicable to newborn infants cared for in facilities 
in well-resourced health-care services.
Implications of all the available evidence
The PREVAIL trial findings contrast with those of previous 
randomised controlled trials of antimicrobial-impregnated CVCs, 
which reported substantial reductions in bloodstream infection 
in older children and adults. A possible explanation for this 
difference is that the trials involving children and adults assessed 
CVCs impregnated with minocycline and rifampicin rather than 
the miconazole and rifampicin combination used in this trial. 
Rifampicin might be more effective when combined with a 
synergistic antibacterial (minocycline) rather than an antifungal 
(miconazole) and a simple, pragmatic randomised controlled 
trial of minocycline and rifampicin-impregnated percutaneously 
inserted CVCs in newborn infants might now be warranted.
See Online for appendix
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The parent or legal representative of the baby gave written 
informed consent for inclusion in the trial.
Randomisation and masking
Participants were randomly assigned (1:1) to receive either 
an antimicrobial-impregnated PICC or a standard PICC, 
by use of a secure web-based randomisation programme 
by the principal investigator or a delegated other individual 
at the site. Enrolment was done by the principal investigator 
or a delegated other individual at the site. The random-
isation programme was centrally controlled by the Clinical 
Trials Research Centre (University of Liverpool, Liverpool, 
UK) to ensure allocation concealment. Randomisation 
sequences were computer-generated by an independent 
statistician in random blocks of two and four and stratified 
by site. Masking of clinicians to PICC allocation was 
impractical because rifampicin caused brown staining of 
the antimicrobial-impregnated PICC. However, participant 
inclusion in analyses and occurrence of outcome events 
were determined by following an analysis plan that was 
specified before individuals saw unblinded data.
Procedures
Trial participants were randomly allocated to receive 
either a miconazole and rifampicin-impregnated PICC 
(Premistar; Vygon, Swindon, UK) or standard (non-
impregnated) PICC (Premicath; Vygon).
PICC insertion was done according to standard unit 
policy and practice. Miconazole is an anti-fungal agent, 
which is effective against systemic fungal infection. 
Rifampicin is an antibacterial agent that has been 
previously evaluated in rifampicin and minocycline 
CVC impregnation in adults and children. Vygon 
reported continuing elution from the CVC impregnated 
with rifampicin and miconazole over 21 days.15 
The antimicrobial-impregnated PICC was marketed 
after appropriate certification under the Conformité 
Européenne process in December, 2012 (certificate 
number Z/12/02895).
The allocated PICC was inserted within 48 h of random 
assignment, and thereafter a standard PICC was used. 
Infection outcomes were captured for all babies until 
48 h after PICC removal or following the last unsuccessful 
PICC insertion or random assignment (if insertion 
was not attempted). Follow-up for secondary clinical out-
comes continued until the infant was discharged to go 
home, death, or 6 months after randomisation, whichever 
occurred first. Follow-up for all deaths continued until 
6 months after randomisation.
Outcomes
The primary outcome was the time from random 
allocation to first bloodstream or cerebrospinal fluid 
(CSF) infection, defined as a microbiological culture of a 
bacteria or fungus from the blood or CSF sampled for 
clinical reasons. We use the term bloodstream infection 
to mean this combined outcome. The time window for 
sampling for primary and secondary outcomes was 24 h 
after randomisation until 48 h after PICC removal or 
death (or 48 h after randomisation if PICC not inserted). 
We imposed a-priori decision rules to avoid counting pre-
existing bloodstream infection. We excluded microbial 
cultures within the assessment time window if the same 
organism was isolated from blood or CSF and samples 
were taken less than 14 days apart, or if a different 
organism was isolated and samples were less than 24 h 
apart. Multiple infection episodes within the time window 
were considered as distinct infection episodes if positive 
samples for each episode involved the same organism 
and occurred more than 14 days apart or involved different 
organisms and occurred more than 24 h apart.
Secondary outcomes related to infection were as 
follows: the type of organism isolated from bloodstream 
infection meeting primary outcome criteria, the rate of 
bloodstream infection (including recurrent bloodstream 
infection) per 1000 days with PICC, occurrence of one or 
more bloodstream infections, rate of catheter-related 
bloodstream infection (defined by isolation of the same 
organism from the PICC tip and blood or CSF) per 
1000 days with PICC, rifampicin resistance in any isolate 
from blood or CSF culture, rifampicin resistance in any 
isolate from PICC tips, and rifampicin resistance in any 
isolate from blood or CSF culture or from the PICC tip 
(this was added as an additional analysis in version 2.0 of 
the statistical analysis plan, which was approved on 
March 7, 2018, before database lock [study closure]).
Outcomes measured to detect potential biases in 
sampling or treatment on the basis of knowledge of 
PICC allocation were as follows: rate of blood or CSF 
culture sampling per 1000 days with PICC, duration of 
antimicrobial exposure from randomisation up to 48 h 
after line removal, and time to PICC removal.
Clinical secondary outcomes were as follows: chronic 
lung disease, defined as requiring respiratory support 
(mechanical ventilation or continuous positive pressure 
via endotracheal tube or nasal tube) or supplemental 
oxygen at 36 weeks’ postmenstrual age, necrotising 
enterocolitis (Bell stage 2 or 3), treatment for retinopathy 
of prematurity (medical or surgical), abnormalities on 
cranial ultrasound (periventricular leukomalacia or 
intracranial haemorrhage; worst grade of 1 to 4 used in 
analyses), time from random allocation to full milk feeds 
(150 mL/kg per day), total duration of parenteral nutrition 
from random allocation until discharge from neonatal 
care, and death before discharge to go home from 
neonatal care.
Death within 6 months of randomisation and time to 
death were recorded from linked death registration data. 
We recorded occurrence of related adverse events for all 
babies who had a PICC successfully inserted until 48 h 
after PICC removal. For all babies who had a PICC 
successfully inserted, we recorded occurrence of any 
expected or unexpected adverse events considered to be 
related to the PICC until 48 h after PICC removal.
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Statistical analysis
The sample size calculation for the primary outcome was 
based on the log-rank test for equality of survival curves, 
with a 5% significance level and 90% power to detect a 
difference between the treatment groups. We considered 
a 50% reduction in bloodstream infection to be 
conservative, given the results of a network meta-analysis 
by Wang and colleagues16 of catheter-related bloodstream 
infections (mean odds ratio 0·18, upper 95% CI 0·34), 
and the results of the CATCH trial.10 To detect a reduction 
in the proportion of babies with a bloodstream infection 
from 14% in the standard CVC group, which was expected 
based on audit data from three participating neonatal 
units, to 7% in the antimicrobial-impregnated CVC 
group, 79 events were required from 816 babies (408 in 
each group); allowing for 5% loss to follow-up, we 
planned to recruit 858 neonates in total.
We analysed the primary outcome and secondary survival 
outcomes with the log-rank test. We used Kaplan-Meier 
curves to present the numbers at risk and Cox regression to 
calculate hazard ratios (HRs). We analysed binary outcomes 
with Fisher’s exact test and presented relative risks (RRs) 
with 95% CIs. We analysed continuous outcomes with the 
Mann-Whitney U test and presented medians with IQRs 
for each group. We analysed rate outcomes using Poisson 
regression and presented rate ratios with 95% CIs. 
Descriptive results only are presented for the type of 
organisms isolated from bloodstream infections, related 
adverse events, and serious adverse events.
We analysed outcome data according to the intention-to-
treat principle. Babies who were randomly assigned but 
had no PICC inserted were assessed for infection-related 
outcomes until 48 h after the last attempted insertion or 
48 h after randomisation. We excluded babies for whom a 
PICC was not inserted from safety analyses, as these 
analyses were undertaken with groups defined by the 
PICC used.
All statistical tests were two-sided, with a 5% significance 
level. All analyses were done with SAS software, version 9.4. 
Results from the primary outcome and safety analyses 
were validated by independent programming by another 
independent statistician from the point of raw data.
We did four prespecified sensitivity analyses of the 
primary outcome as follows: time to serious bloodstream 
infection, defined as treatment with antimicrobials for 
72 h or longer or death during treatment; time from PICC 
insertion to first bloodstream infection; time to first 
bloodstream infection, excluding samples obtained via 
arterial cannulas or CVCs; and time to first bloodstream 
infection, including clearly path ogenic organisms 
and excluding skin organisms (eg, coagulase-negative 
staphylococci). For comparability with published studies 
we also reported bloodstream infection rates per 1000 days 
with PICC between randomisation and PICC removal.
After seeing the results of the primary analysis, we 
specified an additional post-hoc analysis of the primary 
outcome to investigate whether the treatment effect 
varied by gestational age at birth (before 28 weeks of 
gestation or at 28 weeks or more of gestation) using a 
Cox proportional hazards model, including an interaction 
between treatment and gestational age.
The study was monitored by an independent Data 
Monitoring Committee who made recommendations to 
the Trial Steering Committee. An internal pilot study was 
done to show the feasibility of recruitment after the first 
6 months and an interim analysis of the primary outcome 
was done after around half of the babies had been 
randomly assigned.
The trial is registered with ISRCTN, number 81931394.
Role of the funding source
The funder appointed independent members to the 
Trial Steering Committee and Data Monitoring 
Committee, approved all protocol amendments, and 
monitored study progress against agreed milestones. 
The funder had no involvement in data interpretation 
or writing of the report. The corresponding author had 
full access to all outputs from the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between Aug 12, 2015, and Jan 11, 2017, we randomly 
assigned 861 babies to receive an antimicrobial-
impregnated PICC (430 babies) or standard PICC 
(431 babies) (figure 1). Parents of 487 babies who received 
431 allocated to standard PICC
 407 received allocated PICC
 8 received non-allocated PICC
 16 did not receive any PICC
431 included in intention-to-treat
 analysis
3 lost to follow-up after primary 
    outcome time window complete
430 allocated to 
         antimicrobial-impregnated PICC
 373 received allocated PICC
 28 received non-allocated PICC
 29 did not receive any PICC
430 included in intention-to-treat
 analysis
5 lost to follow-up
 4 after primary outcome time 
 window complete 
 1 during primary outcome 
time window
1404 parents or legal guardians approached
861 randomised
543 excluded
 467 declined consent
 76 consented but not randomly assigned
Figure 1: Trial profile
PICC=peripherally inserted central venous catheter. 
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a PICC (French gauge 1) and who would have been eligible 
for inclusion in the study were not approached for consent 
(appendix). Recruitment ended earlier than planned 
(Jan 11, 2017) because the recruitment target was met. 
Clinical follow-up continued until May 30, 2017.
715 (83%) of 861 babies were enrolled in the trial before 
7 days of age and 754 (88%) were born before 32 weeks of 
gestation (table 1). Slightly more babies randomised to 
Antimicrobial-
impregnated PICC 
(n=430)
Standard PICC 
(n=431)
Baseline characteristics
Sex
Male 214 (50%) 225 (52%)
Female 216 (50%) 206 (48%)
Birthweight (g) 962·5 (729–1220) 960·0 (770–1250)
<750 119 (28%) 92 (21%)
750 to <1000 110 (26%) 140 (32%)
1000 to <1250 102 (24%) 91 (21%)
1250 to <1500 52 (12%) 62 (14%)
1500 to <1750 27 (6%) 27 (6%)
1750 to <2000 8 (2%) 7 (2%)
≥2000 12 (3%) 12 (3%)
Gestational age at birth 
(weeks)
27·90 (25·78–29·94) 28·06 (26·23–30·14)
<26 115 (27%) 93 (22%)
26 to <28 101 (23%) 110 (26%)
28 to <30 103 (24%) 102 (24%)
30 to <32 54 (13%) 76 (18%)
32 to <34 28 (7%) 15 (3%)
34 to <36 7 (2%) 9 (2%)
36 to <38 5 (1%) 3 (1%)
≥38 7 (2%) 11 (3%)
Missing 10 (2%) 12 (3%)
<32 373 (87%) 381 (88%)
Major congenital anomaly
Yes 21 (5%) 27 (6%)
No 408 (95%) 404 (94%)
Missing data 1 (<1%) 0
Age (days) 4·12 (2·04–5·93) 3·90 (1·90–6·12)
<2 106 (25%) 113 (26%)
2 to <7 256 (60%) 240 (56%)
7 to <14 39 (9%) 52 (12%)
14 to <21 6 (1%) 11 (3%)
21 to <28 3 (1%) 5 (1%)
≥28 20 (5%) 10 (2%)
Apgar score at 5 min
0–3 23 (5%) 19 (4%)
4–7 138 (32%) 140 (32%)
8–10 247 (57%) 249 (58%)
Missing data 22 (5%) 23 (5%)
Delivery characteristics
Location of birth
Born in study hospital 340 (79%) 367 (85%)
Transferred after birth 90 (21%) 64 (15%)
Mode of delivery
Vaginal 196 (46%) 198 (46%)
Caesarean 234 (54%) 233 (54%)
(Table 1 continues in next column)
Antimicrobial-
impregnated PICC 
(n=430)
Standard PICC 
(n=431)
(Continued from previous column)
Membrane rupture >24 h before delivery
Yes 111 (26%) 104 (24%)
No 299 (70%) 310 (72%)
Missing data 20 (5%) 17 (4%)
Maternal antenatal corticosteroids
Yes 375 (87%) 381 (88%)
No 53 (12%) 50 (12%)
Missing data 2 (<1%) 0
Maternal antibiotics ≤12 h before delivery
Yes 135 (31%) 102 (24%)
No 275 (64%) 310 (72%)
Missing data 20 (5%) 19 (4%)
Neonatal care
Surgery before randomisation
>6 days before 2 (<1%) 3 (1%)
≤6 days before 15 (3%) 10 (2%)
No surgery 413 (96%) 418 (97%)
Positive blood culture <72 h before randomisation
Yes 29 (7%) 19 (4%)
No 401 (93%) 412 (96%)
Antibiotics or antifungals <72 h before randomisation (excluding 
prophylaxis)
Yes 367 (85%) 363 (84%)
No 63 (15%) 68 (16%)
Respiratory support <72 h before randomisation
Invasive ventilation 262 (61%) 257 (60%)
Non-invasive 
ventilation
122 (28%) 133 (31%)
Oxygen only 9 (2%) 7 (2%)
None 37 (9%) 34 (8%)
Devices in situ at randomisation
<4 370 (86%) 390 (90%)
≥4 60 (14%) 41 (10%)
Randomly assigned PICC
PICC insertion site
No PICC inserted 29 (7%) 16 (4%)
Lower limb 207 (48%) 220 (51%)
Upper limb 191 (44%) 190 (44%)
Scalp 3 (1%) 3 (1%)
Other 0 1 (<1%)
Missing 0 1 (<1%)
Data are n (%) or median (IQR). PICC=peripherally inserted central venous 
catheter.
Table 1: Baseline characteristics, clinical condition at randomisation, 
and details of the intervention according to random PICC allocation
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the antimicrobial-impregnated PICC group did not have 
the allocated PICC inserted (table 2). Endpoints for 
follow-up are shown in tables 2, 3.
The time from random allocation to first bloodstream 
or CSF infection was similar between the two groups 
(HR 1·11, 95% CI 0·73–1·67; table 4, figure 2). The 
Kaplan-Meier curves crossed when the numbers at risk 
were low. A time varying coefficient was added to the 
model to check the assumption of proportional hazards, 
and this was not significant (p=0·62; data not shown). 
We observed similar results to our primary outcome 
findings in our sensitivity analyses (table 4).
We found no evidence of a difference in treatment 
effect for babies with a gestational age of less than 
28 weeks compared with 28 weeks or more (p=0·28; 
appendix). 46 (11%) of 430 babies in the antimicrobial-
impregnated PICC group had one or more blood-
stream infections, and three (7%) of these babies had 
two infection episodes. 44 (10%) of 431 babies in the 
standard PICC group had one or more bloodstream 
infections, and one (2%) of these had a second infection 
episode.
Secondary infection-related outcomes were similar 
between the trial groups, with the exception of rifampicin 
resistance from PICC tip cultures (RR 3·51, 95% CI 
1·16–10·57; p=0·018). We found no significant difference 
when comparing the two groups for rifampicin resistance 
from blood, CSF, or PICC tip cultures combined 
(RR 1·80, 0·84–3·86; p=0·13; table 4). We noted the 
organisms isolated during the primary outcome time 
window, which were pre dominantly coagulase-negative 
staphylococci in both trial groups (appendix). We also 
recorded rifampicin-resistant isolates by type of organism 
(appendix). Measures of blood or CSF sampling are 
shown in table 4. Fewer than half of the babies in each 
trial group had one or more blood or CSF samples taken 
(table 3). The rate of blood sampling for suspected 
infection was significantly higher in the antimicrobial-
impregnated PICC group than in the standard PICC 
group (97·90 per 1000 days with antimicrobial-
impregnated PICC vs 79·64 per 1000 days with standard 
PICC; rate ratio 1·23, 95% CI 1·05–1·45; p=0·012; 
table 4). We found no significant differences in the 
median time to PICC removal (8·20 days [IQR 4·77–12·13] 
in the antimicrobial-impregnated PICC group vs 7·86 days 
[5·00–12·53] days in the standard PICC group; HR 1·03, 
95% CI 0·89–1·18, p=0·73) or in the median duration of 
antimicrobial treatment (3 days [IQR 2–6] in both groups; 
p=0·25; table 4). We found no significant differences in 
any clinical outcomes measured at discharge from the 
neonatal unit or in mortality within 6 months of 
randomisation (table 4).
We recorded summary data of the most frequent 
adverse events (table 5). 60 events were reported from 
49 (13%) babies in the antimicrobial-impregnated PICC 
group and 50 events were reported from 45 (10%) babies 
in the standard PICC group. One serious adverse event 
involving supra ventricular tachycardia following PICC 
placement was reported in the antimicrobial-impregnated 
PICC group.
Antimicrobial-impregnated 
PICC (n=430)
Standard PICC 
(n=431)
PICC status
Allocated PICC inserted 373 (87%) 407 (94%)
Non-allocated PICC 
inserted
28 (7%) 8 (2%)
No PICC inserted 29 (7%) 16 (4%)
PICC insertion 
attempted
17 (4%) 9 (2%)
PICC insertion not 
attempted
12 (3%) 7 (2%)
End of follow-up for outcomes that required samples
48 h after PICC removal 387 (90%) 398 (92%)
Death with PICC in situ 13 (3%) 18 (4%)
48 h after 
randomisation
29 (7%) 15 (3%)
Lost to follow-up 1 (<1%) 0
End of follow-up for outcomes that did not require samples
Discharge to home from 
neonatal care
383 (89%) 385 (89%)
Transfer to 
non-participating site
4 (1%) 3 (1%)
Death before discharge 36 (8%) 33 (8%)
6 months after 
randomisation
6 (1%) 10 (2%)
Data are n (%). PICC=peripherally inserted central venous catheter.
Table 2: PICC insertion status and endpoint of follow-up
Antimicrobial-impregnated PICC 
(n=430)
Standard PICC 
(n=431)
Total samples or 
babies with 
positive culture
Babies sampled or 
with positive 
culture tested
Total samples or 
babies with 
positive culture
Babies sampled or 
with positive 
culture tested
Culture samples taken*
Blood or CSF 379 198 (46%) 329 190 (44%)
Peripheral venous 
blood
321 183 (43%) 268 178 (41%)
CSF 40 33 (8%) 38 34 (8%)
Other 18 16 (4%) 23 20 (5%)
PICC tip 314 313 (73%) 310 310 (72%)
Babies with rifampicin resistance tested in positive cultures†
Blood or CSF 48 21 (44%) 46 25 (54%)
Peripheral venous 
blood
44 21 (48%) 42 23 (55%)
CSF 0 0 3 1 (33%)
Other 5 0 3 2 (67%)
PICC tip 47 32 (68%) 90 61 (68%)
PICC=peripherally inserted central venous catheter. CSF=cerebrospinal fluid. *Data are total samples taken (n) and 
the babies from whom samples were taken (n [%]) as a proportion of the total number of babies with 
antimicrobial-impregnated PICCs or standard PICC. †Data are total babies with positive culture (n) and the 
proportion of babies with at least one positive culture tested (n [%]).
Table 3: Sampling for primary and secondary endpoints
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Antimicrobial-impregnated 
PICC (n=430)
Standard PICC (n=431) HR (95% CI), rate ratio 
(95% CI), or RR (95% CI)*
p value
Primary outcome
Time to first bloodstream infection† 46 (11%) 44 (10%) 1·11 (0·73–1·67) 0·63
Sensitivity analyses
Assessed for time to first clinically serious 
bloodstream infection
42 (10%) 40 (9%) 1·11 (0·72–1·71) 0·65
Assessed for time to first bloodstream 
infection (from insertion)  
45 (10%) 44 (10%) 1·08 (0·71–1·64) 0·72
Assessed for time to first bloodstream 
infection, excluding arterial or PICC 
samples
45 (10%) 43 (10%) 1·11 (0·73–1·68) 0·64
Assessed for time to first bloodstream 
infection, excluding skin organisms
16 (4%) 9 (2%) 1·90 (0·84–4·31) 0·12
Secondary outcomes
Rate of bloodstream infection, per 1000 days 
with PICC
13·15 10·87 1·21 (0·78–1·88) 0·40
Sensitivity analysis
Rate of bloodstream infection (when line is 
in situ), per 1000 days with PICC‡
12·57 11·21 1·12 (0·73–1·12) 0·60
Rate of catheter-related bloodstream 
infection, per 1000 days with PICC
1·84 2·35 0·78 (0·27–2·25) 0·65
Sensitivity analysis
Rate of catheter-related bloodstream 
infection (when line is in situ), 
per 1000 days with PICC‡
1·71 2·46 0·70 (0·25–1·96) 0·49
Rate of blood or CSF culture sampling, 
per 1000 days with PICC
97·90 79·64 1·23 (1·05–1·45) 0·012
Sensitivity analysis
Rate of blood or CSF sampling (line in situ), 
per 1000 days with PICC‡
93·72 82·01 1·14 (0·98–1·34) 0·095
Occurrence of one or more bloodstream 
infections
46 (11%) 44 (10%) 1·05 (0·71–1·55) 0·82
Rifampicin resistance from blood or CSF 
culture
4 (1%) 7 (2%) 0·57 (0·17–1·94) 0·55
Rifampicin resistance from PICC tip culture 14 (3%) 4 (1%) 3·51 (1·16–10·57) 0·018
Rifampicin resistance from blood or CSF or 
PICC tip culture§
18 (4%) 10 (2%) 1·80 (0·84–3·86) 0·13
Chronic lung disease 190 (44%) 178 (41%) 1·07 (0·92–1·25) 0·41
Necrotising enterocolitis (Bell stage 2 or 3) 41 (10%) 46 (11%) 0·89 (0·59–1·32) 0·57
Treatment for retinopathy of prematurity 40 (9%) 30 (7%) 1·34 (0·85–2·11) 0·21
Abnormality on cranial ultrasound 166 (39%) 150 (35%) 1·11 (0·93–1·33) 0·26
Death before discharge 36 (8%) 33 (7%) 1·09 (0·70–1·72) 0·71
Death within 6 months of randomisation 36 (8%) 35 (8%) 1·03 (0·66–1·61) 0·90
Time to PICC removal, days‡ 8·20 (4·77–12·13) 7·86 (5·00–12·53) 1·03 (0·89–1·18) 0·73
Time to full milk feeds, days 9·51 (6·37–17·26) 9·40 (6·32–16·37) 0·99 (0·86–1·14) 0·85
Time to death within 6 months of 
randomisation†
NA NA 1·06 (0·67–1·70) 0·79
Antimicrobial treatment, days 3·00 (2·00–6·00) 3·00 (2·00–6·00) NA 0·25
Parenteral nutrition, days 11·00 (7·00–19·00) 10·00 (7·00–18·00) NA 0·83
Data are n (%) or median (IQR), unless otherwise indicated. For all outcomes that relate to samples, events were only considered on samples taken between 24 h after 
randomisation until 48 h after removal. PICC=peripherally inserted central venous catheter. HR=hazard ratio. RR=relative risk. CSF=cerebrospinal fluid. NA=not applicable. 
*HRs (95% CIs) are given for primary outcome data and time to event data; rate ratios (95% CIs) are given for secondary outcomes pertaining to rate data; and RRs (95% CIs) 
are given for all other data. †Median time to event not reported as not enough babies had an event. ‡Only includes babies where PICC was successfully inserted 
(antimicrobial-impregnated PICC: 401 babies; standard PICC: 415 babies). §Outcome not prespecified in protocol but requested by investigators and included in statistical 
analysis plan before any unmasked data were seen.
Table 4: Primary and secondary outcomes in babies randomised to antimicrobial or standard PICC (intention-to-treat analysis)
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Discussion
We found no evidence of benefit or harm from miconazole 
and rifampicin-impregnated PICCs in babies receiving 
intensive care. The 95% CI for the primary outcome 
excluded a 27% reduction or 67% increase in the time 
to bloodstream infection associated with using an 
antimicrobial-impregnated PICC compared with a 
standard PICC, and similar results were found in the 
sensitivity analyses. We found no differences between the 
two groups for mortality at 6 months or clinical outcomes 
recorded at discharge home from the neonatal unit.
The strengths of the trial are the large sample size and 
the multicentre, nationally representative sample of 
babies admitted for neonatal intensive care, which was 
adequately powered to detect a halving of the bloodstream 
infection risk. As 754 (88%) babies participating in the 
trial were born before 32 weeks of gestation, this trial 
provides important new evidence for a group at high risk 
of infection, who have frequent use of PICCs, but for 
whom trial evidence is lacking.13,14 The pragmatic trial 
design, with no additional sampling, and use of a primary 
outcome on the basis of positive cultures taken as part of 
clinical practice in response to suspected infection to 
guide antibiotic treatment, ensured relevance to routine 
practice. Although blood culture is relatively insensitive, 
we found no difference in clinical outcomes such as 
duration of antibiotics or PICC insertion.
We used central web-based randomisation to ensure 
allocation concealment, achieved almost complete 
follow-up and assessment of the primary outcome, 
adhered to a prespecified statistical analysis plan for 
intention-to-treat analyses, and halted recruitment once 
the sample size was achieved. Baseline characteristics 
were well balanced at randomisation. Slightly fewer 
babies in the anti microbial-impregnated PICC group 
received the allocated PICC, probably because the 
randomly assigned PICC had to be inserted within 48 h; 
thereafter, the standard PICC was used. The proportion 
of babies in the standard PICC group with bloodstream 
infection (44 [10%] of 431 babies) was lower than expected 
(14%) but we had sufficient power to exclude a moderate 
reduction in the risk of bloodstream infection. We 
based the sample size and statistical analyses on the 
proportional hazards assumption. We checked this 
assumption and believe it is reasonably upheld, but 
acknowledge that there could be an impact on study 
power if this is not the case. This study was open label, 
so clinicians could distinguish the type of PICC. We 
found a slightly increased rate of blood culture sampling 
in the antimicrobial-impregnated PICC group, but the 
proportions of babies with at least one blood or CSF 
culture or any PICC tip culture were similar and there 
were no differences in the timing of PICC removal 
between trial groups.
A limitation of this study was the insufficient power to 
detect significant differences in rifampicin-resistant 
organisms isolated from blood or CSF cultures. The low 
number of resistant organisms was due to few positive 
cultures, and because only 44–54% of these cultures were 
tested for rifampicin resistance. The risk of rifampicin 
resistance in isolates from positive blood or CSF cultures 
did not differ between the trial groups but was significantly 
increased in positive tip cultures from antimicrobial-
impregnated PICCs. Selection of rifampicin-resistant 
Gram-positive bacteria during treatment—if rifampicin is 
used as the sole antibacterial agent—is well recognised.17 
Emergence of resistant organisms was considered by the 
investigators, the Trial Steering Committee, and the Data 
Monitoring Committee, but the risk of adverse events 
arising was viewed as low because the restricted release of 
rifampicin from the catheter surface would be unlikely to 
affect bacteria at any site other than the catheter itself. 
Even if rifampicin-resistant Gram-positive bacteria did 
cause infection in an indi vidual patient, routine antibiotic 
use would be unaffected because rifampicin is rarely used 
for treatment in the neonatal setting.
We found that miconazole and rifampicin impregnation 
did not reduce bloodstream infection in newborn babies. 
This result is consistent with findings from a randomised 
controlled trial in adults and a small randomised 
Antimicrobial-impregnated 
PICC (n=374)
Standard PICC 
(n=430)
Events Babies Events Babies
Any adverse event 60 49 (13%) 50 45 (10%)
Evidence of catheter blockage 15 15 (4%) 15 15 (3%)
Extravasation 11 11 (3%) 11 11 (3%)
Swelling or haematoma at line site 10 10 (3%) 7 7 (2%)
Clinically evident thrombophlebitis 4 4 (1%) 7 7 (2%)
Difficulty removing stylet 8 8 (2%) 1 1 (<1%)
Catheter damage 3 3 (1%) 4 4 (1%)
Data are n or n (%). PICC=peripherally inserted central venous catheter.
Table 5: Adverse events in babies with PICC inserted
Figure 2: Time to first bloodstream infection for newborn babies randomised to antimicrobial-impregnated 
PICC or standard PICC
PICC=peripherally inserted central venous catheter.
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controlled trial in newborn infants published as an 
abstract (appendix).14,18,19 However, our findings contrast 
with evidence of reduced catheter-related bloodstream 
infection in adults and reductions in any bloodstream 
infection in children randomised to minocycline and 
rifampicin-impregnated CVCs versus standard CVCs.10,20,21 
Several explanations could account for these differ-
ences. First, miconazole and rifampicin might be less 
effective than minocycline and rifampicin impregnation. 
Miconazole is used to prevent invasive fungal infection in 
preterm babies, which is rare in the UK, but has a very 
high mortality.8 Few babies in our trial had fungal 
bloodstream infection, consistent with a recent UK 
study.22 However, rifampicin might be less effective when 
used as the sole antibacterial agent combined with 
miconazole. Rifampicin is more active against Gram-
positive than against Gram-negative bacteria and has 
synergistic action against staphylococci when combined 
with another antibacterial drug—eg, minocycline—
especially against methicillin-resistant strains.17,23
Second, although the combination of minocycline and 
rifampicin has been reported as the most effective type 
of antimicrobial impregnation in systematic reviews,24,25 
it is possible that minocycline and rifampicin-
impregnated CVCs might not effectively reduce overall 
incidence of bloodstream infection or sepsis.26 A network 
meta-analysis of seven randomised trials in adults 
showed beneficial effects of antimicrobial impregnation 
for catheter-related blood stream infection,25 but few 
trials have measured the effect on any bloodstream 
infection.10 Catheter-related infection requires the same 
isolates from blood and CVC tip and could be prone to 
bias because of inhibition of positive tip cultures by 
leaching of antimicrobial from the tip during plating out 
for culture. Only the large CATCH trial10 in children 
used any clinically indicated bloodstream infection as 
the primary outcome and found a 57% reduction in time 
to infection (appendix). A smaller trial27 compared 
catheter-related bloodstream infection in children 
randomly assigned to minocycline and rifampicin-
impregnated CVC or standard CVC and found no 
difference in the rate of catheter-acquired bloodstream 
infection, but detected few infection events (three in 
each group; appendix).27 Third, reductions in infection 
rates in neonatal units associated with improved catheter 
asepsis practices and shorter duration of PICC use 
might have narrowed the potential for further benefits 
from antimicrobial impregnation.28 PICCs also might 
not be an independent risk factor for infection in sick 
preterm babies because of their high susceptibility to 
infection from multiple sources, due to numerous 
invasive procedures and devices, gut permeability, and 
immune immaturity.29
Since 2012, the Premistar PICC has been the only 
antimicrobial-impregnated PICC available for preterm 
babies in Europe. Use of Premistar has been reported in 
Germany and Italy,14 but, to our knowledge, use in the 
UK has been limited to the PREVAIL trial. The trial 
findings do not support the use of miconazole and 
rifampicin-impregnated PICCs in newborn infants, as 
we found no evidence that antimicrobial-impregnated 
PICCs reduced bloodstream infections and such PICCs 
are more expensive than standard PICCs. However, the 
serious life-long consequences of bloodstream infection 
mean that even interventions with relatively small effects 
might be clinically important. One in ten babies in the 
PREVAIL trial had a bloodstream infection and some 
might have serious life-long neurodevelopmental 
impairment or lung disease as a result. Therefore, more 
large trials are urgently needed to reduce the risks of 
bloodstream infection and their long-term consequences. 
Viewed against existing evidence on the effectiveness of 
rifampicin and minocycline-impregnated CVCs in adults 
and children, our findings have implications for the 
manufacturers of these devices and for clinicians. First, 
alternative types of antimicrobial-impregnated PICCs 
should be considered for evaluation in newborn babies, 
along with other interventions to prevent bloodstream 
infection in the neonatal intensive care unit. Second, 
further randomised controlled trials should be considered 
to determine whether previous evidence on the 
effectiveness of antibiotic-impregnated CVCs in adults is 
sustained in the context of effective infection control 
practices.
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